JP2012521346A5 - - Google Patents

Download PDF

Info

Publication number
JP2012521346A5
JP2012521346A5 JP2011547867A JP2011547867A JP2012521346A5 JP 2012521346 A5 JP2012521346 A5 JP 2012521346A5 JP 2011547867 A JP2011547867 A JP 2011547867A JP 2011547867 A JP2011547867 A JP 2011547867A JP 2012521346 A5 JP2012521346 A5 JP 2012521346A5
Authority
JP
Japan
Prior art keywords
seq
ctprosp
human
isolated protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011547867A
Other languages
English (en)
Japanese (ja)
Other versions
JP5801206B2 (ja
JP2012521346A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2010/050097 external-priority patent/WO2010087771A1/en
Publication of JP2012521346A publication Critical patent/JP2012521346A/ja
Publication of JP2012521346A5 publication Critical patent/JP2012521346A5/ja
Application granted granted Critical
Publication of JP5801206B2 publication Critical patent/JP5801206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011547867A 2009-01-30 2010-01-29 アルツハイマー病の治療のための化合物および方法 Active JP5801206B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14854109P 2009-01-30 2009-01-30
EP09151790.4 2009-01-30
EP09151790 2009-01-30
US61/148,541 2009-01-30
PCT/SE2010/050097 WO2010087771A1 (en) 2009-01-30 2010-01-29 Compound and method for treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2012521346A JP2012521346A (ja) 2012-09-13
JP2012521346A5 true JP2012521346A5 (cg-RX-API-DMAC7.html) 2014-03-27
JP5801206B2 JP5801206B2 (ja) 2015-10-28

Family

ID=40707673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011547867A Active JP5801206B2 (ja) 2009-01-30 2010-01-29 アルツハイマー病の治療のための化合物および方法

Country Status (5)

Country Link
US (2) US8785390B2 (cg-RX-API-DMAC7.html)
EP (1) EP2391379B1 (cg-RX-API-DMAC7.html)
JP (1) JP5801206B2 (cg-RX-API-DMAC7.html)
CN (1) CN102300582A (cg-RX-API-DMAC7.html)
WO (1) WO2010087771A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087771A1 (en) * 2009-01-30 2010-08-05 Alphabeta Ab Compound and method for treatment of alzheimer's disease
WO2011162655A1 (en) 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
EP2694977B1 (en) * 2011-04-05 2016-06-29 Alphabeta AB Amyloidosis target useful in methods of screening of compounds
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
CN114107254A (zh) * 2021-11-12 2022-03-01 武汉理工大学 一种重组蛋白DspB-SNa5及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290516A4 (en) 1986-10-24 1989-11-14 Jeffrey A Whitsett PROTEINS RELATED TO SURFACE-EFFECTIVE HYDROPHOBIC LUNG ACTIVE SUBSTANCES.
WO2000071671A2 (en) 1999-05-26 2000-11-30 New York University New mutant genes in familial british dementia and familial danish dementia
US20030224982A1 (en) * 2001-07-05 2003-12-04 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
US6716589B2 (en) 2000-11-20 2004-04-06 Alphabeta Ab Discordant helix stabilization for prevention of amyloid formation
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
BR0317132A (pt) * 2002-12-09 2005-10-25 Chidren S Hospital Medical Ct Métodos de diagnóstico e tratamento de doença pulmonar intersticial
GB0307863D0 (en) * 2003-04-04 2003-05-14 Merck Sharp & Dohme Therapeutic treatment
DK1670903T3 (da) 2003-09-05 2008-01-02 Cellzome Ag Behandling af neurodegenerative sygdomme
EP2369348A1 (en) 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
WO2005055994A1 (en) 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
RU2396090C2 (ru) 2004-04-05 2010-08-10 Дзе Юниверсити Оф Токушима Носитель лекарства-антигена, дающий возможность трансмукозального и трансдермального введения, способ индуцирования мукозального иммунитета, мукозальная вакцина и система доставки лекарства, использующие его
JP2008546701A (ja) 2005-06-14 2008-12-25 イェシバ・ユニバーシティ Aβ産生へのBRI蛋白の効果
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
WO2008066734A2 (en) 2006-11-22 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Transgenic mammals modified bri protein expression
ES2562806T3 (es) * 2007-06-05 2016-03-08 Paka Pulmonary Pharmaceuticals, Inc. Composiciones para administrar medicamentos en los pulmones, y usos de las mismas
US20100298202A1 (en) * 2007-07-06 2010-11-25 Mayo Foundation For Medical Education And Research Bri polypeptides and reducing ab aggregation
WO2010087771A1 (en) 2009-01-30 2010-08-05 Alphabeta Ab Compound and method for treatment of alzheimer's disease
WO2011162655A1 (en) 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
EP2694977B1 (en) 2011-04-05 2016-06-29 Alphabeta AB Amyloidosis target useful in methods of screening of compounds

Similar Documents

Publication Publication Date Title
KR20210027377A (ko) 프로그래뉼린을 포함하는 융합 단백질
JP2018119011A (ja) アルツハイマー病治療方法
US9051364B2 (en) Composition for producing anti-amyloid beta peptide antibodies with D-peptides
AR062065A1 (es) Anticuerpo humanizado
JP2012521346A5 (cg-RX-API-DMAC7.html)
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
Forde et al. Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis
CN103987725A (zh) 具有改善的药代动力学性质的坎普他汀类似物
CN102105485B (zh) 选择性胱天蛋白酶抑制剂及其用途
JP2012115277A5 (cg-RX-API-DMAC7.html)
KR20220130678A (ko) 프로그라눌린 변이체들
CN111057134B (zh) 一类具有广谱抗菌活性、低毒性且无诱导耐药性的抗菌肽及其应用
JP2014506450A5 (cg-RX-API-DMAC7.html)
WO2021247675A1 (en) Coronavirus-binding agents and uses thereof
CN110563802B (zh) 一组含n-甲基化氨基酸及n端脂肪酸修饰的抗菌肽类似物及其合成方法和应用
JP2011522561A5 (cg-RX-API-DMAC7.html)
EP4077348A1 (en) Retro-inverso peptides
RU2010120571A (ru) Тимус-специфический белок
JP2019038772A5 (cg-RX-API-DMAC7.html)
CN101466729A (zh) 溶杆菌素酰胺
JP2015533372A5 (cg-RX-API-DMAC7.html)
RU2015114320A (ru) Пептидные антагонисты рецептора 2 вазопрессина
JP2015525237A5 (cg-RX-API-DMAC7.html)
WO2011144714A1 (en) Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldt- jakob disease or diabetes mellitus
JP5754008B2 (ja) CaMKII阻害ペプチドおよびこれを含有するCaMKII阻害剤